Target Information

Target General Infomation
Target ID
T62005
Former ID
TTDR00244
Target Name
Integrin alpha-V/beta-3
Synonyms
Alpha v beta 3 integrin; Alpha(v)beta(3) Integrin; Integrin alpha-v beta-3; Integrin alphaVbeta3; Vitronectin Receptor
Target Type
Clinical Trial
Disease Melanoma [ICD9: 172; ICD10: C43]
Osteoporosis [ICD9: 733.0, V07.4; ICD10: M80-M81, Z79.890]
Ocular disease [ICD10: H00-H59]
Prostate cancer [ICD9: 185; ICD10: C61]
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
BioChemical Class
Integrin
UniProt ID
P06756||P05106
Drugs and Mode of Action
Drug(s) Cilengitide Drug Info Phase 3 Rheumatoid arthritis [1], [2]
Fluciclatide F-18 Drug Info Phase 2 Solid tumours [3]
Intetumumab Drug Info Phase 2 Prostate cancer [4]
AMEP Drug Info Phase 1 Melanoma [5]
Vitaxin Drug Info Discontinued in Phase 2 Solid tumours [6]
SB-267268 Drug Info Discontinued in Phase 1 Osteoporosis [7]
SB-273005 Drug Info Discontinued in Phase 1 Osteoporosis [8]
PS-388023 Drug Info Terminated Ocular disease [9]
Modulator AMEP Drug Info
Cilengitide Drug Info
Fluciclatide F-18 Drug Info
Intetumumab Drug Info [10]
PS-388023 Drug Info [11]
SB-267268 Drug Info [12]
SB-273005 Drug Info
Vitaxin Drug Info
Antagonist IS20I Drug Info [13]
References
REF 1ClinicalTrials.gov (NCT00689221) Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status. U.S. National Institutes of Health.
REF 2(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6597).
REF 3Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032798)
REF 4ClinicalTrials.gov (NCT00537381) An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer. U.S. National Institutes of Health.
REF 5Pre-EMP-tive strike against GBM. SciBX 7(14); doi:10.1038/scibx.2014.389. April 10 2014
REF 6Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004890)
REF 7Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013716)
REF 8Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013133)
REF 9Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022665)
REF 10A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer. 2011 Jul 26;105(3):346-52.
REF 11Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
REF 12SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1600-5.
REF 13IS20I, a specific alphavbeta3 integrin inhibitor, reduces glioma growth in vivo. Neurosurgery. 2003 Jan;52(1):177-85; discussion 185-6.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.